Inhibition of checkpoint kinase 1 potentiates anticancer activity of gemcitabine in bladder cancer cells
Abstract Checkpoint kinases (CHKs) are involved in the DNA damage response in many cancer cells. CHK inhibitors have been used in clinical trials in combination with chemotherapeutics; however, their effect against bladder cancer remains unclear. Here, we investigated the efficacy of combining gemci...
Saved in:
Main Authors: | Makoto Isono, Kazuki Okubo, Takako Asano, Akinori Sato |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/961e795ec7d4455493f964a2d9a8fa35 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Intravesical gemcitabine for non-muscle invasive bladder cancer: An abridged Cochrane Review
by: Mi Ah Han, et al.
Published: (2021) -
Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
by: Guru Sonpavde, et al.
Published: (2021) -
A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
by: Jun Zhou, et al.
Published: (2013) -
Chitosan–Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study
by: Ostad SN, et al.
Published: (2012) -
9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer
by: Hiroo Kuroki, et al.
Published: (2019)